Shares of Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) were down 21.7% on Friday . The stock traded as low as $1.23 and last traded at $1.57. Approximately 3,201,798 shares were traded during mid-day trading, an increase of 247% from the average daily volume of 921,421 shares. The stock had previously closed at $1.29.
Several analysts have weighed in on CVRS shares. Zacks Investment Research cut shares of Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a research note on Monday, January 29th. Cowen set a $2.00 price objective on shares of Corindus Vascular Robotics and gave the stock a “buy” rating in a research note on Thursday. Three equities research analysts have rated the stock with a sell rating and two have given a buy rating to the stock. Corindus Vascular Robotics has a consensus rating of “Hold” and an average target price of $2.00.
The stock has a market cap of $272.68, a price-to-earnings ratio of -6.67 and a beta of 18.81.
Corindus Vascular Robotics (NYSEAMERICAN:CVRS) last issued its quarterly earnings results on Wednesday, March 14th. The medical equipment provider reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). Corindus Vascular Robotics had a negative net margin of 323.84% and a negative return on equity of 110.93%. The business had revenue of $4.19 million for the quarter, compared to analysts’ expectations of $3.90 million.
Several institutional investors have recently modified their holdings of CVRS. Millennium Management LLC bought a new stake in Corindus Vascular Robotics in the fourth quarter valued at $2,189,000. Deutsche Bank AG boosted its holdings in Corindus Vascular Robotics by 91.6% in the fourth quarter. Deutsche Bank AG now owns 250,179 shares of the medical equipment provider’s stock valued at $251,000 after acquiring an additional 119,611 shares in the last quarter. BlackRock Inc. boosted its holdings in Corindus Vascular Robotics by 4.6% in the fourth quarter. BlackRock Inc. now owns 4,384,539 shares of the medical equipment provider’s stock valued at $4,428,000 after acquiring an additional 191,134 shares in the last quarter. Essex Investment Management Co. LLC boosted its holdings in Corindus Vascular Robotics by 55.2% in the fourth quarter. Essex Investment Management Co. LLC now owns 1,238,664 shares of the medical equipment provider’s stock valued at $1,251,000 after acquiring an additional 440,601 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in Corindus Vascular Robotics by 34.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 383,800 shares of the medical equipment provider’s stock valued at $584,000 after acquiring an additional 97,900 shares in the last quarter.
TRADEMARK VIOLATION WARNING: “Corindus Vascular Robotics (CVRS) Trading Down 21.7%” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/03/18/corindus-vascular-robotics-cvrs-trading-down-21-7.html.
Corindus Vascular Robotics Company Profile
Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.
Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with MarketBeat.com's FREE daily email newsletter.